Specifically, p53 promotes adaptive survival responses to glutamine deprivation in both wild-type and RAS-transformed MEFs, triple-negative breast cancer, pancreatic cancer and human lymphoma cell lines. This evidence concerns the gene TP53 and lymphoma.